-
Opening plenary lecture followed by Household product safety
08:30–08:35 Welcome and opening 08:35-09:20 How can poisons centres prove their worth? Using PCC data with impact!
Lecturer: Senator David Karnes, USA09:20-09:40 Harmonisation of the information relating to emergency health response (Poisons Centre article 45 CLP)
Lecturer: An Jamers, European Commission, Brussels, Belgium09:40-10:00 Harmonisation of information on mixtures under CLP Article 45: an industry perspective
Lecturer: Janice Robinson, CEPE, Brussels, Belgium10:00-10:45 Coffee and electronic posters
E-POSTERS from 1 to 12 (see detailed at E-Posters tab)10:45-11:05 Poisons centres’ case records can increase consumer safety
Lecturer: Herbert Desel, Federal Institute for Risk Assessment, Berlin, Germany11:05-11:25 New legal requirements for submission of product information to Poisons Centres in EU Member States
Lecturer: Ronald de Groot, National Poisons Information Center / University Medical Center, Utrecht, The Netherlands11:25-11:50 Open Forum Panel discussion 11:50-12:05 How and why are liquid laundry detergent products toxic?
Lecturer: J Allister Vale, NPIS (Birmingham Unit), City Hospital, Birmingham, UK12:05-12:20 Referral and treatment guidelines for liquid laundry capsule exposures - a USA view
Lecturer: Bill Banner, Oklahoma Center for Poison and Drug Information, Oklahoma, USA12:20-12:30 General discussion 12:30-14:15 Lunch and posters
Household product safety (continued) followed by Poster discussion session14:15-14:35 The A.I.S.E. accidentology study on liquid detergent capsule exposures
Lecturer: Geert Boeije, Boeije Consulting, Sint-Martens-Latem, Belgium14:35–14:50 Surveillance of pediatric exposure to laundry detergents: Comparison between cases exposed to liquid capsules and traditional products (abstract no. 13)
Lecturer: Laura Settimi, Istituto Superiore di Sanità, Rome, Italy14:50–15:05 Acute and chronic oesophageal injury following caustic ingestions in a 25 year cohort (abstract no.14)
Lecturer: Tim Cowan, Hunter New England Local Health District, Newcastle, Australia15:05–15:20 A review of the toxicity of picaridin-containing insect repellents reported to the National Poison Data System (abstract no. 15)
Lecturer: Jennifer Parker Cote, University of Virginia, Charlottesvile, USA15:20–15:35 Single dose activated charcoal (AC): Application by medical non professionals - a prospective single centre study on availability and quality of administration ((abstract no. 16)
Lecturer: Rudolf Pfab, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany15:35-15:40 General discussion 15:40-16:10 Coffee and electronic posters
E-POSTERS from 18 to 25 (see detailed at E-Posters tab)16:10-17:30 Poster discussion session
CME accreditation will not be requested for this session
- 26. Pattern of acute toxicity related to the use of the novel psychoactive substance methedrone (4-methoxymethcathinone, 4-MeOMC)
- 27. Self-reported use matched with oral fluid analysis of recreational drug use in a South London nightclub
- 28. Outpatient treatment of acute poisoning by substances of abuse: A 1-year prospective observational study
- 30. Increase in unintentional pediatric exposures in a recreational marijuana state
- 31. ADB-Fubinaca in the real world: A case series of 15 poisonings
- 32. Specific issues in acute cannabis poisoning in adolescents
- 33. Novel psychoactive substance (NPS) consumption in binge drinkers: A new and potentially dangerous health risk
- 34. Prospective cohort study to determine low risk acute ethanol intoxications risk factors
- 35. Toxicity following recreational use of synthetic cannabinoid receptor agonists and the impact of legal control measures: A report from the UK's National Poisons Information Service
- 36. Trends in oral anticoagulant enquires to the UK National Poisons Information Service: A retrospective 5 year review
- 37. AfriTox® TeleLog: The development of a novel web-based data collection tool for poison centre call data in South Africa
- 38. Antidotes network: Is it possible to connect stocks between centers?
- 39. Extraordinary mobilizations of antidotes from the National Stockpile to hospital emergency departments: An example of versatility and integration of national functions and systems
- 40. Profile and risk assessment of household cleaners as evaluated from Emergency Department (ED) cases in the Spanish Toxic Surveillance System (STSS) in the last 5 years
- 41. Adverse drugs reactions (ADR) collected by medical-staffed ambulances: A pilot study with the SAMU de Paris
-
Clinical toxicology of cannabis and cannabinoids
09:20-09:40 Epidemiology of cannabis and cannabinoid use
Lecture: Maren Hermanns-Clausen, Poisons Information Center, Center for Pediatrics and Adolescent Medicine, Freiburg, Germany09:40-10:00 Pharmacology of cannabis and cannabinoids
Lecture: Jean-Claude Alvarez, Versailles St Quentin University, Garches, France10:00-10:45 Coffee and electronic posters
E-POSTERS from 1 to 12 (see detailed at E-Posters tab)10:45-11:05 Acute neuropsychiatric effects of cannabis and cannabinoids
Lecture: Robert Hoffman, NYU School of Medicine, New York, USA11:05-11:25 The complex interaction between cannabinoids and psychiatric and cognitive effects
Lecture: Amir Englund, King's College London, London, UK11:25-11:45 Cardiovascular effects of cannabis and cannabinoids
Lecture: Paul Dargan, Guy's and St Thomas' NHS Foundation Trust, London, UK11:45-12:05 Cannabis withdrawal syndrome
Lecture: Régis Bédry, University Hospital Pellegrin, Bordeaux, France12:05–12:20 Acute side effects after consumption of the novel synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA (abstract no. 17 Clinical Toxicology)
Lecture: Maren Hermanns-Clausen, Poisons Information Center, Center for Pediatrics and Adolescent Medicine, Freiburg, Germany12:20–12:30 General discussion 12:30–14:15 Lunch and posters
Best paper session followed by E-cigarettes - the good, the bad and the ugly14:15-15:40 An international panel have each been asked to select a clinical toxicology paper published in the year 2015 that they consider to be among the best. The aim is to highlight papers that have changed or challenged clinical practice, taught something new or unexpected, improved understanding of toxicological mechanisms, or inspired the panellists. The speakers will defend their choice in a brief 10 minute presentation followed by discussion.
Discussants:
Robin Ferner
- Idarucizumab for dabigatran reversal.
Pollack CV Jr, Reilly PA, Eikelboom J, et al.
N Engl J Med. 2015 Aug 6;373(6):511-20. - Andexanet alfa for the reversal of factor Xa inhibitor activity.
Siegal DM, Curnutte JT, Connolly SJ, et al.
N Engl J Med. 2015 Dec 17;373(25):2413-24.
Andis Graudins
- The Safety and Effectiveness of Droperidol for Sedation of Acute Behavioral Disturbance in the Emergency Department.
Calver L, Page CB, Downes MA, et al.
Ann Emerg Med. 2015 Sep;66(3):230-238 - A Randomized Trial of Icatibant in ACE-Inhibitor-Induced Angioedema.
Baş M, Greve J, Stelter K, et al.
N Engl J Med. 2015 Jan 29;372(5):418-25
Sergej Zacharov
- Metabolic methanol: molecular pathways and physiological roles.
Dorokhov YL, Shindyapina AV, Sheshukova EV, et al.
Physiol Rev. 2015 Apr;95(2):603-44 - Age-related formaldehyde interferes with DNA methyltransferase function, causing memory loss in Alzheimer's disease.
Tong Z, Han C, Qiang M, et al.
Neurobiol Aging. 2015 Jan;36(1):100-10
NB CME accreditation has not been requested for this session.15:40-16:10 Coffee and electronic posters
E-POSTERS from 18 to 25 (see detailed at E-Posters tab)16:10-16:30 Background on use of e-cigarettes - what is the current picture?
Lecture: Esther A Croes, Trimbos Institute, Utrecht, The Netherlands16:30-16:50 Poison centre experience with cases involving e-cigarettes
Lecture: Lies Scholtens, National Poisons Information Center, University Medical Center, Utrecht, The Netherlands16:50-17:10 E-cigarettes: are they being used to vape recreational drugs and new psychoactive substances (NPS)?
Lecture: David Wood, Guy's and St Thomas' NHS Foundation Trust, London, UK17:10-17:30 An integrated assessment approach for candidate Modified Risk Tobacco Products
Lecture: Manuel Peitsch, Philip Morris International, Neuchatel, Switzerland - Idarucizumab for dabigatran reversal.
